Hepatitis C in the HIV-infected person

被引:300
作者
Sulkowski, MS [1 ]
Thomas, DL [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21231 USA
关键词
D O I
10.7326/0003-4819-138-3-200302040-00012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Because of shared routes of transmission, hepatitis C virus (HCV) infection is common in HIV-infected persons, who have been experiencing increasing HCV-related morbidity and mortality since the advent of effective antiretroviral therapy. Infection with HIV appears to adversely affect the outcome of hepatitis C, leading to increased viral persistence after acute infection, higher levels of viremia, and accelerated progression of HCV-related liver disease. In addition, hepatitis C may affect the course and management of HIV infection. The medical management of hepatitis C in HIV-infected persons is complicated by immune suppression, potential drug interactions and toxicities, and other forms of liver disease. In addition, there is little published experience with the safety and efficacy of the best available anti-HCV medications in HIV-infected persons. Thus, current efforts must be directed at preventing HCV and HIV infections and applying the principles learned in treating persons with either infection to manage those with both. Future efforts should include studies of the pathogenesis of HCV infection in HIV-infected persons and large, prospective studies that demonstrate the optimal management of persons co-infected with HIV and HCV. Such efforts will help to eliminate HCV-related liver disease as an emerging threat to HIV-infected persons.
引用
收藏
页码:197 / 207
页数:11
相关论文
共 124 条
[81]  
Núñez M, 2001, J ACQ IMMUN DEF SYND, V27, P426, DOI 10.1097/00126334-200108150-00002
[82]   Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection [J].
Palella, FJ ;
Delaney, KM ;
Moorman, AC ;
Loveless, MO ;
Fuhrer, J ;
Satten, GA ;
Aschman, DJ ;
Holmberg, SD .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) :853-860
[83]   CURRENT CONCEPTS - MOTHER-TO-CHILD TRANSMISSION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS [J].
PECKHAM, C ;
GIBB, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (05) :298-302
[84]   HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time [J].
Perelson, AS ;
Neumann, AU ;
Markowitz, M ;
Leonard, JM ;
Ho, DD .
SCIENCE, 1996, 271 (5255) :1582-1586
[85]  
Perronne C, 2002, HEPATOLOGY, V36, p283A
[86]   Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? [J].
Piroth, L ;
Duong, M ;
Quantin, C ;
Abrahamowicz, M ;
Michardiere, R ;
Aho, LS ;
Grappin, M ;
Buisson, M ;
Waldner, A ;
Portier, H ;
Chavanet, P .
AIDS, 1998, 12 (04) :381-388
[87]   Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users [J].
Pol, S ;
Lamorthe, B ;
Thi, NT ;
Thiers, V ;
Carnot, F ;
Zylberberg, H ;
Berthelot, P ;
Bréchot, C ;
Nalpas, B .
JOURNAL OF HEPATOLOGY, 1998, 28 (06) :945-950
[88]   Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV) [J].
Poles, MA ;
Dieterich, DT ;
Schwarz, ED ;
Weinshel, EH ;
Lew, EA ;
Lew, R ;
Scholes, JV .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 11 (02) :170-177
[89]   Natural history of liver fibrosis progression in patients with chronic hepatitis C [J].
Poynard, T ;
Bedossa, P ;
Opolon, P .
LANCET, 1997, 349 (9055) :825-832
[90]   Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus [J].
Poynard, T ;
Marcellin, P ;
Lee, SS ;
Niederau, C ;
Minuk, GS ;
Ideo, G ;
Bain, V ;
Heathcote, J ;
Zeuzem, S ;
Trepo, C ;
Albrecht, J .
LANCET, 1998, 352 (9138) :1426-1432